In a companion article, we describe the engineering and characterization of pituitary GH3 cell clones stably transfected with a furin-cleavable human insulin cDNA (InsGH3 cells). This article describes the perfor mance of InsGH3 (clones 1 and 7) cell grafts into streptozotocin (STZ)-induced diabetic nude mice. Subcuta neous implantation of 2 x 10 6 InsGH3 cells resulted in the progressive reversal of hyperglycemia and diabetic symptoms, even though the progressive growth of the transplanted cells (clone 7) eventually led to glycemic levels below the normal mouse range. Proinsulin transgene expression was maintained in harvested InsGFG grafts that, conversely, lose the expression of the prolactin (PRL) gene. Elevated concentrations of circulating mature human insulin were detected in graft recipients, demonstrating that proinsulin processing by InsGH3 cells did occur in vivo. Histologic analysis showed that transplanted InsGH3 grew in forms of encapsulated tumors composed of cells with small cytoplasms weakly stained for the presence of insulin. Conversely, intense insulin immunoreactivity was detected in graft-draining venules. Compared to pancreatic pTC3 cells, lnsGH3 cells showed in vitro a higher rate of replication, an elevate resistance to apoptosis induced by serum deprivation and proinflammatory cytokines, and significantly higher antiapoptotic Bcl-2 protein levels. Moreover, InsGH3 cells were resistant to the streptozotocin toxicity that, in contrast, reduced PTC3 cell viability to 50-60% of controls. In conclusion, proinsulin gene expression and mature insulin secretion persisted in transplanted InsGH3 cells that reversed hyperglycemia in vivo. InsGH3 cells might represent a potential P-cell surrogate because they are more resistant than pancreatic p cells to different apoptotic insults and might therefore be particularly suitable for encapsulation.
INTRODUCTION
Diabetes cell therapy depends on the implantation of insulin-producing cells in sufficient number and quality to survive long enough to restore the pancreatic endo crine function and to escape from autoimmune recogni tion. Recent improvements in the field of immunoisola tion membranes, which allow transplantation in the absence of systemic immunosuppression (6) , gave impe tus to search for xenogeneic islets (19) or P-cell lines (2) (3) (4) 6, 7, 15, 16, 20, 24, 28, 33) for encapsulation-based di abetes cell therapy. Encapsulated cells must be supplied with oxygen and nutrients by diffusion from the closest blood vessels, surrounding tissue, and immunoisolation membrane. The distance from the nearest blood vessels determines a gradient in oxygen and nutrients supply that is often unbearable for the p cells (6) , which are normally extremely well perfused (3) . Indeed, P-cell se cretion and viability are extremely susceptible to hy poxia and other cytotoxic stresses (12, 21, 29) . Immediate loss of islet tissue, as a result of oxygen supply limita tion and aspecific inflammation, has also been shown in naked syngeneic transplantation (8) .
P-cell vulnerability, as well as p-cell-directed cyto toxicity present in autoimmune diabetes, raises the ra tionale of using non-p cells for diabetes cell therapy. Previous studies suggested that GH3 cells might be a logical substrate for engineering an artificial P cell, even though they express the receptor-type protein tyrosine phosphatase IA-2a (36) , which is an islet autoantigen of type I diabetes (32) . Indeed, a cytotoxic antibody that binds to rat pancreatic islet cells and RIN cells, but not to GH3 cells, has been described in the NOD mouse (31) . Moreover, splenic lymphoid cells cytotoxic to ma jor histocompatibility complex (MCH)-compatible Wistar-Furth rat islets and also to MCH-incompatible Lewis rat islets and RIN cells, but not to GH3 cells, have been described in diabetic BB rats (26) . In addi tion, cytotoxic cell-mediated immunoreactivity selec tively against a P-cell line was also observed in the mul tiple low-dose streptozotocin-induced rodent model of autoimmune diabetes (27) .
The rationale of developing insulin-secreting non-P cells also applies to encapsulation. Indeed, shed P-cell antigens might foster an inflammatory reaction around the capsule, leading to pericapsular fibrosis and suffoca tion of encapsulated cells (6) . Furthermore, shed anti gens from encapsulated P cells might perpetuate or reac tivate autoimmunity against the residual recipient's pancreatic P cells that often survive for years after the diagnosis of type I diabetes. GH3 cells are also attractive because their original secretory products (rat prolactin and growth hormone) do not exert biological effects on human tissues due to the species specificity of the hu man receptors (18, 37) , even though their secretory prod ucts might still be immunogenic. Finally, xenogeneic InsGFD cells, being highly phylogenetically distant, should be promptly rejected in case of leakage from en capsulation devices, thereby minimizing the safety con cerns related to the use of transformed cell lines into humans.
In this study we explored the performance of insulinsecreting pituitary GH3 cell (InsGFB cells, described in a companion article, this issue) implants performed in STZ-diabetic mice. We also compared the vulnerability of InsGFB and PTC3 cells to a variety of toxic agents. Our data indicate that InsGFB cells might be a potential P-cell surrogate for encapsulation-based cell therapy even though additional engineering is required.
MATERIALS AND METHODS

Cells and Cell Cultures
Rat pituitary GH3 (American Type Culture Collec tion), mouse pancreatic PTC3 cells, and proinsulintransfected InsGH3 cells (clones 1 and 7) were cultured as previously described in the companion article.
Cell Growth In Vitro
Proliferation was determined by cell counting with a Coulter Counter ZM (Beckman, Coulter Inc., CA, USA). InsGH3 (clones 1 and 7), wild-type GH3, and pTC3 cells were plated onto six multiwell plates and cultured under standard conditions. Cells were then harvested and counted 2, 4, 6, and 8 days after plating.
Detection of Apoptosis
Apoptosis was determined by using a DNA fragmen tation assay (13) . Briefly, InsGH3 cells of both clones and pTC3 cells (<50% confluent) cultured for 5 days in 25-cm 2 tissue culture flask in their standard tissue cul ture medium supplemented or not with 10% FCS, or in the presence of a cocktail of cytokines (IL-1 50 IU/ml + TNF-a 1000 Ul/ml + IFN-y 1000 Ul/ml) were washed and resuspended in 100 pi of lysis buffer (10 mM Tris-HCl/10 mM EDTA/0.5% Triton X-100, pH 8.0) and sonicated. After centrifugation for 20 min at 4°C (14,000 xg), the supernatant-containing fragmented (soluble) DNA was transferred to another tube. Lysis buffer (100 pi) was added to the pellet containing insol uble DNA. Samples were then treated with Rnase for 1 h and then with proteinase-K for another hour. After adding isopropanol, samples were incubated overnight at -20°C, and the DNA concentrations were measured by the method of Duke and Sellins (13) . Fragmented DNA was calculated as 100% x soluble DNA/soluble + insoluble DNA. The soluble fraction of DNA was deter mined by electrophoresis on 1.8% agarose gel.
MTT Viability Assay
Viability of InsGH3 (clones 1 and 7) and pTC3 cells cultured 5 days in the presence of the same mixture of cytokines described above, or exposed for 1 h to increas ing concentrations of streptozotocin (2 and 10 mmol/L; Sigma, St. Louis, MO), was measured by using the MTT (tetrazolium) colorimetric assay (22) .
Western Blotting
Bcl-2 protein levels in PTC3, GH3 wild-type, and InsGH3 clones were measured by Western blotting and anti-Bcl-2 antibody (rabbit anti goat 1:100; Santa Cruz, Biotechnology, USA).
Insulin Assays
Circulating insulin levels in mice bearing InsGH3 grafts were measured by using a IRMA (SANOFI, Pasteur Institute, Paris, France), which recognizes only human mature insulin and split 65-66, and does not cross-react with the other (pro)insulin forms. Circulating human proinsulin levels were measured by ELISA (Dako Diagnostic, Ely, UK), which does not cross-react with insulin and other split proinsulin forms. Human Cpeptide levels were measured by RIA (Diagnostic Prod uct Corporation, LA, USA).
Transplantation Experiments
Male nude mice (Nu/Nu, 6-8 weeks old) were ren dered diabetic by injecting a single dose of STZ (180 mg/kg body weight, IP). Diabetes was confirmed by the presence of hyperglycemia (>350 mg/dl), weight loss, and polyuria. Random (nonfasted) glycemic levels were measured (between 0900 and 1000 h) on whole blood obtained from the snipped mouse tail with a portable glucose meter (One Touch II, Johnson & Johnson, Milpitas, CA). The animals were kept under conventional conditions in climatized rooms with free access to water and food. Three groups of diabetic mice were implanted subcutaneously between the shoulders with aliquots of 2 x 10 6 wild-type GH3 cells and InsGH3 cells of clones 1 and 7. After implantation, mice were followed with re peated measurements of blood glucose levels and body weight. At the time of sacrifice grafts were retrieved and RNA was extracted for the analysis of proinsulin trans gene expression by Northern blotting analysis. Naive pancreases were also harvested and immunostained for insulin as previously described (9) in order to detect re sidual P cells. Finally, blood samples were collected for the measurement of circulating mature human insulin levels. To determine proinsulin processing by trans planted InsGH3 cells, circulating human insulin, proin sulin, and C-peptide levels were measured in the same samples drawn from normal nude mice that were trans planted 2 weeks earlier with 2 x 10 6 InsGH3/clone 7.
Northern Blot Analysis
At the time of sacrifice the grafts were harvested and divided into two parts. One half of each graft was used to measure the expression of the human proinsulin and rat PRL genes in either wild-type GH3 or InsGH3 cell implants. Immediately after harvesting, total graft RNA was prepared with the ULTRASPEC RNA isolation sys tem (Biotecx Laboratories Inc., Houston, TX). Northern blot analysis was performed as described in the compan ion article (this issue).
Graft Morphology and Immunohistochemistry
The second half of the harvested grafts (wild-type GH3 and InsGH3 implants) underwent histologic analy sis. Morphology and immunohistochemistry were per formed on formalin-fixed, paraffin-embedded speci mens. After deparaffinization and rehydration, 5-pm sections were stained with hematoxylin-eosin and im munostained for insulin (guinea pig anti-porcine 1:1500; Eurodiagnostica, Malmo, Sweden). Slides were blocked for 30 min in 5% normal goat serum and 0.1% Triton X-100 in phosphate-buffered saline (PBS) and exposed overnight to the primary antibodies. Sections were then washed and incubated with the secondary antibodies for 1 h at room temperature. The specific staining was de tected using the ABC immunoperoxidase system (Vectastatin, Vector, Burlingame, CA) as chromogen.
In Situ Hybridization
Graft specimens were cleared of paraffin with xylene and rehydrated by sequential washings with graded etha nol solutions (70-95%). After three washes in PBS buffer, sections were deproteinated by incubation (20 min, room temperature) with proteinase K (10 pg/ml) in 10 mM Tris buffer, pH 7.5, containing 2 mM CaCl 2 .
Deproteinated tissues were rinsed in 2x SSC for 10 min and then prehybridized for 3 h at room temperature with prehybridization buffer (50% formamide, 4x SSC, 2x Denhardt's, 0.1% SDS, 100 pg/ml salmon sperm DNA). Hybridization was performed with 8 ng/pl of proinsulin digoxigenin-labeled RNA probe (sense or antisense) in hybridization solution (i.e., prehybridization buffer with 10% dextran sulfate). Slides were covered with parafilm and incubated at 42°C for 16 h in a humidified chamber. After hybridization, sections were washed twice in 4x SSC and then incubated with Rnase A (50 pg/ml) for 30 min at 3°C. Posthybridization treatment was performed by incubation of sections in 2x SSC, 0.1% SDS (twice for 15 min/each), 2x SSC (15 min), lx SSC (15 min). To detect digoxigenin-labeled probe, tissue was rinsed briefly in TBS buffer, blocked for 7 h in 100 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% BSA, and 0.3% Triton X-100 and then incubated with an anti-digoxigenin antibody, conjugated to alkaline phosphatase (Boeh ringer Mannheim), diluted 1:400. The specific signals were visualized by incubation in developing buffer (100 mM Tris-HCl, pH 9.5, 100 mM NaCl, and 50 mM MgCl 2 ), containing 0.34 mg/ml of nitrotetrazolium blue, 0.17 mg/ml of 5-bromo-4-chloro-3-indolylphosphate, and 0.024% levamisole. Developing reaction was stopped with 10 mM Tris-HCl, pH 7.5; sections were dehydrated with graded ethanol solutions (70-95%) and mounted.
Statistical Analysis
Experiments were repeated at least three times. Data were expressed as means ± SE. Statistical analysis was performed using the unpaired Student's Mest for pairwise comparisons and one-or two-way analysis of vari ance (ANOVA) for multiple comparisons. Statistical significance was considered at p < 0.05.
RESULTS
Cell Growth
As shown in Figure 1 , InsGH3 cells of clones 1 and 7 proliferated in vitro significantly faster than wild-type GH3 and pTC3 cells (p < 0.01 at day 7 and p < 0.001 at day 9 vs. GH3 and pTC3). PTC3 cells grew with the longest doubling time (approximately 68 vs. 24 h of InsGH3 clones) and reached a maximal density of 4.4 x 10 4 cell/cm 2 , which was about 10-fold lower than the maximal density of InsGH3 clone 7 (1.4xl0 5 cells/ cm 2 ).
Apoptosis
Both InsGH3 clones were extremely resistant to apoptosis induced by serum deprivation and proinflam matory cytokines. In InsGH3 cells no evidence of DNA fragmentation was detected after 5 days of culture in the absence of serum, while massive apoptosis was detected , with a doubling time of about 24 h, was significantly higher than that of wild-type GH3 and (3TC3 cells (*p < 0.01 at day 7, and #p < 0.001 at day 9 vs both GH3 and |3TC3). (3TC3 showed the lowest replication rate with an approximate doubling time of 68 h. Data are mean ± SE of six independent experi ments, performed in duplicate.
in (3TC3 cells (Fig. 2, top) . In InsGH3 cells of clone 1, serum deprivation increased DNA laddering from a baseline of 0.02% to 0.4%, and in InsGFD of clone 7 from 0.01% to 0.5%; in contrast, in PTC3 cells baseline laddering was 0.4% that increased to 24% in the absence of serum (Fig. 2, bottom) . InsGFD cells (clones 1 and 7) were also more resistant than PTC3 to apoptosis in duced by proinflammatory cytokines. The percentage of fragmented DNA after exposure to cytokines was 9.8%
in InsGFD clone 1, 5.5% in InsGFD clone 7, and 30% in PTC3 cells (Fig. 3) .
MTT Viability Assay
This test measured the reduction of tetrazolium salt into insoluble colored formazan crystals. Exposure of InsGFD (clones 1 and 7) to 2 and 10 mmo/L STZ did not induced any significant decrease in formazan pro duction, thereby indicating the absence of cytotoxicity.
In contrast, 2 mmol/L STZ induced a 55% decrease in formazan production by PTC3 cells, indicating a mas sive loss in PTC3 viability that did not decreased any further at 10 mmol/L STZ (Fig. 4) .
A five-day exposure of InsGFD (clones 1 and 7) and
PTC3 cells to the same mixture of proinflammatory cy tokines utilized for the induction of apoptosis resulted in a decreased viability of PTC3 and InsGFD cells (clones 1 and 7) to 51 ± 11%, 62+ 11%, and 57 ± 10% of con trols, respectively (NS).
Bcl-2 Protein Levels
Western blotting experiments showed the absence of measurable Bcl-2 protein in PTC3 cells. In contrast, Bcl-2 protein was abundant in wild-type GH3 cells and in InsGFD of both clones even though it was signifi cantly higher in clone 1 than in clone 7 and in wild-type GH3 cells ( Fig. 5 ).
Transplantation Experiments
Results of subcutaneous implantation of wild-type Northern blot analysis showed the expression of the pro insulin gene in InsGFB grafts of either clone 1 and 7, while it was negative in wild-type GH3 grafts (Fig. 6,   top ). Conversely, PRL gene expression was positive in wild-type GH3 grafts, but negative in InsGFB grafts of both clones. Note that in InsGFB cells of clone 7 the PRL gene expression was also low before the implanta tion ( Fig. 6, top) .
Graft Morphology and Immunohistochemistry
Histology and of (3TC3 cells exposed for 1 h to increasing concentrations of STZ assessed by using the MTT (tetrazolium) method. InsGH3 cell viability remained stable after the exposure to 10 mmol/L STZ; in contrast, viability of (3TC3 decreased to 55% of control values already at the lower STZ concen tration (2 mmol/L) and did not increased further at 10 mmol/L. Data are mean ± SE of three individual experiments. *p < 0.001 vs control.
well-vascularized tissue composed of cells with small cytoplasms almost completely negative for insulin that, conversely, was extremely intense in the venules drain ing the grafts (Fig. 7) . Similar findings were observed in either clone 1 and 7 grafts (not shown). Immunohisto chemistry for insulin did not show any residual (J cells in the pancreases of mice implanted with InsGH3 cells (not shown).
In Situ Hybridization
Proinsulin digoxigenin-labeled RNA probes demon strated the expression in situ of the transfected proinsu lin gene in InsGH3 grafts (Fig. 8 ).
DISCUSSION
The aim of cell therapy is to replace or enhance the biological function of damaged tissue or organs. Encap sulation of chromaffin cells for chronic pain (23) and genetically engineered immortalized cells for neurode generative diseases have been demonstrated experimen tally and are being tested clinically (1, 17) . Cell therapy of type I diabetes relies on the replacement of the func tion of pancreatic (3 cells, which are selectively targeted and destroyed by the autoimmune process responsible for the disease (38) . Endocrine non-p cells are an ap pealing alternative for insulin gene delivery in type I diabetes because they might escape autoimmune recog nition and the recurrence of graft destruction.
InsGH3 (clones 1 and 7) grew in vitro remarkably faster than pTC3 and wild-type GH3 cells (Fig. 1) . Insu lin might stimulate cell growth and division either by acting through its own receptor or the IGF-1 receptor (5) , which is present in GH3 cells (34) . Therefore, insu lin might activate downstream signaling pathways in tivity of their cytoplasms. Such a reduced insulin stor age, together with the high plasmatic insulin levels de tected in the recipients, indicates that in transplanted InsGH3 cells the constitutive release of insulin prevails on the regulated secretion, perhaps more than what is observed in vitro (see companion article). High constitu tive release of insulin might put the recipient of InsGH3 cells at risk of hypoglycemia in the postabsorptive state, even if the control of graft growth is achieved by encap sulation. Therefore, strategies aimed towards reducing constitutive and possibly increasing regulated insulin se cretion need to be implemented before InsGH3 cells could be considered suitable candidates for human dia betes cell therapy.
The capability of transplanted InsGH3 to produce and release insulin is remarkable, as previous studies have shown that the PRL promoter activity is selectively si lenced in transplanted GH3 cells (10, 11) . Indeed, PRL gene expression was undetectable in transplanted InsGH3, while PRL gene expression was maintained in transplanted wild-type GH3 cells (Fig. 6 ). Lack of ex pression of the PRL gene by transplanted InsGH3 cells is an obvious advantage for our purpose. We cannot make any conclusion regarding growth hormone (GH) graft expression nor GH serum concentrations, which were not measured in InsGH3 graft-bearing mice.
Serum deprivation induced substantial apoptosis in (3TC3 cells, while it was almost ineffective on InsGH3 cells (Fig. 2) . Cytokines induced a similar apoptotic cell death in (JTC3 cells, but had a limited impact on InsGH3 cells (Fig. 3) . Alterations in Bcl-2 mRNA and protein levels have been related to apoptosis induced by cyto kines either in MIN6 and RINm5F P-cell lines (21) . The P-cell line (PTC1) is extremely sensitive to cytokineinduced apoptosis that, conversely, is barely detectable in the a-cell line (aTCl), which is characterized by sig nificantly higher Bcl-2 mRNA and protein levels (29) . Moreover, it has been recently demonstrated that lentivirus-mediated overexpression of Bcl-2 in PTC-tet cells significantly improves their resistance to hypoxia and cytokine-induced apoptosis (14) . Therefore, our obser vation that Bcl-2 protein is relatively abundant in wildtype GH3 and InsGH3 cell clones could explain the resistance to apoptosis observed in InsGH3 cells, com pared with PTC3 cells. It should be noted that long-term exposure to proinflammatory cytokines reduced InsGH3 and PTC3 viability, measured by the MTT assay, to a similar extent, therefore suggesting that InsGH3 cells Lanes from left to right represent: |3TC3 cells, wild-type (WT) GH3, InsGH3/ clone 1, InsGH3/clone 7 (before transplantation for all cell types), WT GH3 graft, InsGH3/clone 1 graft, and InsGFB/clone 7 graft. Note that the expression of the proinsulin gene was present in InsGFB grafts of both clones, which, in contrast, were negative for PRL gene expression. Con versely, PRL gene was highly expressed in WT GH3 grafts. Note also that PRL gene expression was already low in InsGFB cells of clone 7 before the implantation. Lower panel shows the glycemic levels of STZ-diabetic nude mice transplanted with either wild-type (WT) GH3 cells or InsGFB cells of clones 1 and 7. As expected, WT GH3 grafts did not determine any reduction in blood glucose levels. In contrast, mice transplanted with InsGFB cells of clone 7 showed a progres sive decline in blood glucose that, 4 weeks after implantation, was below the normal mouse range (*p < 0.05 vs. WT GH3; #p < 0.001 vs. WT GH3; %p < 0.01 vs. InsGFB of clone 1). Implantation of InsGFB cells of clone 1 induced a slower decrease in glycemic levels that 5 weeks later were still in the diabetic range even though lower than before transplantation, and of those measured in mice bearing WT GH3 grafts ( §p < 0.02). Recipients of InsGFB/clone 1 cells were allowed to survive longer after transplantation, showing a progressive decrease in glycemic levels that, 10 weeks after transplantation, reached values approaching the normal range. Data are mean + SE.
are not protected by cytokine-mediated necrotic cell death. Noteworthy, InsGFB cells were also resistant to streptozotocin-induced cell damage. Streptozotocin acts either via alkylation of DNA or through the release of bioactive nitric oxide (NO) (25) . Whatever the cause of the insensitivity of InsGFB cells to STZ, such a feature appears as an additional advantage for transplantation purposes. The different response of InsGFB and pTC3 cells to STZ is not explained by a differential expression of the glucose transporter GLUT-2 that, in other p cell lines, has been pointed as the mediator of STZ toxicity (35) . Indeed, we did not detect GLUT-2 protein in either wild-type GH3, InsGH3, or pTC3 cells (not shown). The absence of GLUT-2 expression by PTC3 cells, pre viously shown by others (30) , suggests that STZ toxicity involves a GLUT-2-independent pathway in pTC3 cells.
In conclusion, because of their elevated resistance to a variety of insults, InsGH3 cells appear particularly suited for encapsulation. Moreover, InsGH3 cells will probably also allow a greater packing density within the capsules as suggested by the 10-fold higher maximal density reached by these cells in vitro compared with pTC3 cells. The achievement of physiologic regulation of insulin release by InsGH3 cells, and the reduction of their constitutive pathway of protein secretion, will greatly increase the potential of these cells for transplan tation.
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